BullFrog AI (NASDAQ: BFRG; BFRGW) introduced that its VP of Artificial Intelligence, Dr. Enrique García-Rivera, will current at Google’s inaugural Cancer AI Symposium on October 30, 2024, in Boston. The presentation will showcase BullFrog AI’s use of AI in drug discovery and improvement, specializing in their proprietary bfLEAP™ platform. This platform integrates multimodal organic information to speed up drug improvement, significantly in most cancers analysis.
Dr. García-Rivera will spotlight the corporate’s collaboration with the Lieber Institute for Mind Improvement, demonstrating bfLEAP™’s versatility throughout numerous therapeutic areas. He may also introduce BullFrog AI’s novel ‘AlgoLLM’ system for gene prioritization, which makes use of massive language fashions to streamline the invention of actionable insights in neuropsychiatric issues and different illnesses.
BullFrog AI (NASDAQ: BFRG; BFRGW) ha annunciato che il suo VP di Intelligenza Artificiale, il Dr. Enrique García-Rivera, presenterà al simposio inaugurale sull’AI per il cancro di Google il 30 ottobre 2024, a Boston. La presentazione mostrerà come BullFrog AI utilizzi l’AI nella scoperta e nello sviluppo di farmaci, concentrandosi sulla loro piattaforma proprietaria bfLEAP™. Questa piattaforma integra dati biologici multimodali per accelerare lo sviluppo dei farmaci, in particolare nella ricerca sul cancro.
Il Dr. García-Rivera metterà in evidenza la collaborazione dell’azienda con l’Istituto Lieber per lo Sviluppo del Cervello, dimostrando la versatilità di bfLEAP™ in vari ambiti terapeutici. Introdurrà anche il nuovo sistema ‘AlgoLLM’ di BullFrog AI per la priorizzazione dei geni, che utilizza modelli linguistici di grandi dimensioni per semplificare la scoperta di intuizioni praticabili nei disturbi neuropsichiatrici e in altre malattie.
BullFrog AI (NASDAQ: BFRG; BFRGW) anunció que su VP de Inteligencia Artificial, el Dr. Enrique García-Rivera, presentará en el simposio inaugural de AI sobre el cáncer de Google el 30 de octubre de 2024, en Boston. La presentación destacará el uso de la IA por parte de BullFrog AI en el descubrimiento y desarrollo de medicamentos, centrándose en su plataforma propietaria bfLEAP™. Esta plataforma integra datos biológicos multimodales para acelerar el desarrollo de medicamentos, especialmente en la investigación del cáncer.
El Dr. García-Rivera resaltará la colaboración de la compañía con el Instituto Lieber para el Desarrollo del Cerebro, demostrando la versatilidad de bfLEAP™ en diversas áreas terapéuticas. También presentará el novedoso sistema ‘AlgoLLM’ de BullFrog AI para la priorización de genes, que emplea modelos de lenguaje de gran tamaño para simplificar el descubrimiento de información procesable en trastornos neuropsiquiátricos y otras enfermedades.
BullFrog AI (NASDAQ: BFRG; BFRGW)는 자사의 인공지능 부사장인 엔리케 가르시아-리베라 박사가 2024년 10월 30일 보스턴에서 구글의 첫 번째 암 AI 심포지엄에서 발표할 것이라고 발표했습니다. 발표는 BullFrog AI가 약물 발견과 개발에 AI를 어떻게 활용하는지를 보여주며, 그들의 독점 플랫폼인 bfLEAP™에 중점을 둘 것입니다. 이 플랫폼은 다중 모드 생물학적 데이터를 통합하여 약물 개발을 가속화하는 데 특히 암 연구에서 중요한 역할을 합니다.
가르시아-리베라 박사는 뇌 발달을 위한 리버 연구소와의 협업을 강조하며, bfLEAP™의 다양한 치료 분야에서의 다재다능함을 보여줄 것입니다. 또한, BullFrog AI의 새로운 유전자 우선순위 지정 시스템인 ‘AlgoLLM’을 소개할 예정이며, 이는 대규모 언어 모델을 사용하여 신경 정신 질환 및 기타 질병에서 실용적인 통찰력을 발견하는 과정을 간소화합니다.
BullFrog AI (NASDAQ: BFRG; BFRGW) a annoncé que son VP de l’Intelligence Artificielle, le Dr Enrique García-Rivera, présentera lors du premier symposium sur l’IA du most cancers de Google le 30 octobre 2024 à Boston. La présentation mettra en avant l’utilisation de l’IA par BullFrog AI dans la découverte et le développement de médicaments, en se concentrant sur leur plateforme propriétaire bfLEAP™. Cette plateforme intègre des données biologiques multimodales pour accélérer le développement de médicaments, en particulier dans la recherche sur le most cancers.
Le Dr García-Rivera soulignera la collaboration de l’entreprise avec l’Institut Lieber pour le Développement du Cerveau, démontrant la polyvalence de bfLEAP™ dans divers domaines thérapeutiques. Il présentera également le nouveau système ‘AlgoLLM’ de BullFrog AI pour la priorisation des gènes, qui utilise des modèles linguistiques de grande taille pour simplifier la découverte d’informations exploitables dans les troubles neuropsychiatriques et d’autres maladies.
BullFrog AI (NASDAQ: BFRG; BFRGW) gab bekannt, dass der VP für Künstliche Intelligenz, Dr. Enrique García-Rivera, am 30. Oktober 2024 auf dem ersten Krebs-AI-Symposium von Google in Boston sprechen wird. Die Präsentation wird die Verwendung von KI durch BullFrog AI in der Arzneimittelentdeckung und -entwicklung zeigen und sich auf die proprietäre bfLEAP™-Plattform konzentrieren. Diese Plattform integriert multimodale biologische Daten, um die Arzneimittelentwicklung, insbesondere in der Krebsforschung, zu beschleunigen.
Dr. García-Rivera wird die Zusammenarbeit des Unternehmens mit dem Lieber Institute for Mind Improvement hervorheben und die Vielseitigkeit von bfLEAP™ in verschiedenen therapeutischen Bereichen demonstrieren. Er wird auch das neuartige ‘AlgoLLM’-System von BullFrog AI zur Priorisierung von Genen vorstellen, das große Sprachmodelle nutzt, um die Entdeckung umsetzbarer Erkenntnisse bei neuropsychiatrischen Störungen und anderen Krankheiten zu vereinfachen.
Constructive
- Presentation at Google’s prestigious Cancer AI Symposium enhances firm visibility
- Showcasing proprietary bfLEAP™ platform demonstrates technological management in AI-driven drug improvement
- Collaboration with Lieber Institute for Mind Improvement highlights platform versatility
- Introduction of novel ‘AlgoLLM’ system for gene prioritization reveals continued innovation
GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) — BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Firm”), a technology-enabled drug improvement firm utilizing synthetic intelligence (AI) and machine studying to allow the profitable improvement of prescription drugs and biologics, at this time introduced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will current at Google’s inaugural Cancer AI Symposium on October 30, 2024, at the Boston Heart for the Arts.
Dr. García-Rivera’s presentation will showcase BullFrog AI’s groundbreaking use of synthetic intelligence in drug discovery and improvement. Highlighting the Firm’s proprietary bfLEAP™ platform, the presentation will discover how multimodal organic information—together with genomics, transcriptomics, and scientific information—are built-in to speed up the drug improvement course of.
A key side of the presentation will probably be how bfLEAP™ is utilized to most cancers analysis, leveraging AI to establish advanced organic patterns that contribute to illness development and remedy resistance. Dr. García-Rivera may also reference BullFrog AI’s collaboration with the Lieber Institute for Mind Improvement as a primary instance of how bfLEAP™ is being utilized throughout numerous therapeutic areas. The collaboration, which focuses on neurological issues comparable to bipolar dysfunction, underscores the platform’s versatility and potential to drive innovation throughout a number of domains, together with most cancers.
Dr. García-Rivera may also introduce BullFrog AI’s novel “AlgoLLM” system for gene prioritization, which revolutionizes the identification of high-priority targets in drug improvement by harnessing massive language fashions. This modern AI device is vital for streamlining the invention of actionable insights in neuropsychiatric issues and different illnesses, advancing the Firm’s mission to develop more practical and personalised remedies.
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine studying to advance drug discovery and improvement. By collaborations with main analysis establishments, BullFrog AI makes use of causal AI together with its proprietary bfLEAP™ platform to analyze advanced organic information, aiming to streamline therapeutics improvement and scale back failure charges in scientific trials.
For extra data go to BullFrog AI at: https://bullfrogai.com
Protected Harbor Assertion
This press launch comprises forward-looking statements. We base these forward-looking statements on our expectations and projections about future occasions, which we derive from the knowledge presently obtainable to us. Such forward-looking statements relate to future occasions or our future efficiency, together with: our monetary efficiency and projections; our development in income and earnings; and our enterprise prospects and alternatives. You’ll be able to establish forward-looking statements by these that aren’t historic in nature, significantly those who use terminology comparable to “could,” “ought to,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the damaging of those or comparable phrases. In evaluating these forward-looking statements, you must contemplate numerous elements, together with: our capacity to change the route of the Firm; our capacity to maintain tempo with new know-how and altering market wants; and the aggressive setting of our enterprise. These and different elements could trigger our precise outcomes to differ materially from any forward-looking assertion. Ahead-looking statements are solely predictions. The forward-looking occasions mentioned on this press launch and different statements comprised of time to time by us or our representatives, could not happen, and precise occasions and outcomes could differ materially and are topic to dangers, uncertainties, and assumptions about us. We aren’t obligated to publicly replace or revise any forward-looking assertion, whether or not on account of uncertainties and assumptions, the forward-looking occasions mentioned on this press launch and different statements comprised of time to time by us or our representatives won’t happen.
Contact:
Dave Gentry
RedChip Firms, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ
When and the place will BullFrog AI (BFRG) current at Google’s Cancer AI Symposium?
BullFrog AI’s VP of Artificial Intelligence, Dr. Enrique García-Rivera, will current at Google’s inaugural Cancer AI Symposium on October 30, 2024, at the Boston Heart for the Arts.
What is going to BullFrog AI (BFRG) showcase at the Google Cancer AI Symposium?
BullFrog AI will showcase its proprietary bfLEAP™ platform, demonstrating the way it integrates multimodal organic information to speed up drug improvement, significantly in most cancers analysis.
What’s BullFrog AI’s (BFRG) new gene prioritization system referred to as?
BullFrog AI has developed a novel gene prioritization system referred to as ‘AlgoLLM’, which makes use of massive language fashions to streamline the invention of actionable insights in drug improvement.
What collaboration will BullFrog AI (BFRG) spotlight in its presentation?
BullFrog AI will spotlight its collaboration with the Lieber Institute for Mind Improvement, specializing in neurological issues comparable to bipolar dysfunction, to reveal the flexibility of its bfLEAP™ platform.